Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors
Qurient, a clinical-stage biotech company based in Korea, has announced that the first patient has […]
Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology
Oricell Therapeutics, an innovative pharmaceutical company committed to the development of clinical-stage oncology cell therapies, […]
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
Cell BioEngines, a cell and gene therapy company focused on developing an allogenic cell-based product […]
Crown Bioscience to Acquire Indivumed Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has […]
Ono Pharmaceutical to Acquire Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics
KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using […]
VITRAC Therapeutics Initiates a Phase 1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
VITRAC Therapeutics initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with […]
Ferronova Secures A$11 Million to Advance Nanotech Image-guided Cancer Therapy
Australian biotech company Ferronova has announced it has secured a further A$11 million to progress […]
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma
Linnaeus Therapeutics, a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of […]
Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
Tallac Therapeutics, a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity […]
First Patient Dosed in CANbridge Pharmaceuticals Trial for the Treatment of Gaucher Disease in China
CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more